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Abstract
Background Few population-based epidemiological data
are available on Merkel cell carcinoma (MCC), a rare
lethal non-melanoma skin cancer. We analysed multiple-
cause-of-death records to describe MCC mortality and
trends and the association with other primary cancers.
Methods We reviewed all 6,713,059 death certiﬁcates in
Italy (1995–2006) to identify those mentioning MCC. We
evaluated the association with other primary cancers by
calculating the ratio of observed to expected deaths, using a
standardized mortality ratio (SMR)-like analysis. We also
evaluated the geographic distribution of deaths.
Results We identiﬁed 351 death certiﬁcates with the
mention of MCC. The age-adjusted mortality was 0.031/
100,000, with a signiﬁcant trend of increase and a slight
north–south gradient. There was a signiﬁcant deﬁcit for
solid cancers (SMR = 0.15) and a non-signiﬁcant excess
for lymphohematopoietic malignancies (SMR = 1.62).
There were signiﬁcant excesses for chronic lymphocytic
leukemia (SMR = 4.07) and Waldenstro ¨m’s macroglobu-
linemia (SMR = 27.2) and a non-signiﬁcant excess for
chronic myeloid leukemia (SMR = 5.12).
Conclusions The increase in MCC mortality reﬂects the
incidence trend in the literature. The association with
chronic lymphocytic leukemia conﬁrms the importance of
immunologic factors in MCC. Regarding Waldenstro ¨m’s
macroglobulinemia, an association with MCC has never
been reported.
Keywords Multiple-cause-of-death  Non-melanoma
skin cancer  Waldenstro ¨m’s macroglobulinemia  Chronic
lymphocytic leukemia  Neuroendocrine carcinoma
Introduction
Merkel cell carcinoma (MCC) is a rare neuroendocrine
cancer of the skin that usually affects elderly persons [1–3].
MCC has been recently shown to be associated with a
virus, ‘‘Merkel-cell-polyomavirus’’ [4]. An increased risk
of MCC has been reported among solid-organ transplant
recipients [5, 6] and persons with HIV/AIDS [6, 7], and
some studies have reported an association between MCC
and other cancers, such as chronic lymphocytic leukemia
[8–11]. MCC is considered to be highly aggressive and
lethal [1, 2]; in fact, more than half of the persons with
non-localized MCC die within 1 year of diagnosis [11].
Given the rarity of MCC, few population-based epide-
miological data are available, and these data, which derive
from cancer registries, have become available only
recently. In Europe, the only published data for individual
countries are incidence data for Denmark and Sweden [11,
12]. For other rare tumours or diseases for which few data
are available, multiple-cause-of-death records have been
used as a source of data [13, 14]. The advantage to using
these records is that they are a readily available source of
population-based information on the health status of a
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underlying cause of death, those other diseases or condi-
tions that contributed to death [15].
With speciﬁc regard to Italy, the only data on the
incidence of MCC are those derived by applying the
morphology code for MCC (M8247/3) (International
Classiﬁcation of Diseases for Oncology; Edition 3; ICD-O-
3) to data from the Italian Association of Cancer Registries
(AIRTUM) (0.28 per 100,000 population in 2001–2005;
95% CI: 0.25–0.32; AIRTUM, personal communication).
However, these data are unpublished in this form (i.e.,
MCC is generally pooled with other types of non-mela-
noma skin cancer), and the Italian network of registries
only covers about one-third of the country’s population
(AIRTUM; http://www.registri-tumori.it/cms/). In light of
the limited data available, we conducted a study based on
the analysis of the multiple-cause-of-death database. The
objective of the study was to use mortality data as an
epidemiological indicator for MCC in Italy. In particular,
the data were used to estimate the occurrence of MCC,
including its geographic distribution and temporal trends,
and to identify other concomitant conditions and potential
associations with other primary cancers.
Materials and methods
Identiﬁcation of deceased persons with MCC
To identify deceased persons with MCC, we used the
multiple-cause-of-death database, which is managed
by Italy’s National Institute of Statistics (ISTAT;
www.istat.it). This database consists of individual anon-
ymous electronic records that contain the underlying
cause of death and all causes as typewritten out in full by
the medical examiner on the death certiﬁcate; the causes
of death are not coded. This database currently contains
records for the period 1995–2006 and covers Italy’s entire
population (about 57,000,000). We considered both per-
sons with MCC recorded as the underlying cause on the
death certiﬁcate (i.e., death due to MCC) and those with
MCC recorded as another cause or condition but who had
another underlying cause (i.e., death with MCC). We
reviewed all 6,713,059 records in the period 1995–2006
and identiﬁed those with the term ‘‘Merkel’’ written
anywhere on the death certiﬁcate. In this way, 345
records were identiﬁed, yet 8 were eliminated because we
deemed that the term ‘‘Merkel’’ was a misspelling of the
name of another pathology [‘‘Merkel diverticulum’’
(n = 6), ‘‘Merkel cave’’ (n = 1), and ‘‘Merkeloma of the
lung’’ (n = 1)]. We included another 14 death certiﬁcates
on which ‘‘Merkel’’ was written, yet incorrectly [‘‘Meckel
cell carcinoma’’ (n = 9), ‘‘Mekel cell carcinoma’’
(n = 2), and ‘‘Mechel cell carcinoma’’ (n = 3)]. Thus, a
total of 351 records were identiﬁed.
For the 351 records, we conducted a descriptive analy-
sis, which included demographic information, the ana-
tomical site of MCC, and the diffusion of MCC at death
(i.e., whether it was localized or non-localized and whether
there were regional lymph node metastases or distant
metastases). We also considered the most relevant diseases
or conditions other than MCC mentioned on the death
certiﬁcates; when more than one of these diseases or con-
ditions was recorded on the death certiﬁcate, we identiﬁed
the most important one based on its position on the cer-
tiﬁcate (i.e., underlying cause, other causes resulting in the
underlying cause, other signiﬁcant conditions, or immedi-
ate/ﬁnal cause of death) and on the hierarchy of conditions
used in ICD-10. To determine whether the age distribution
signiﬁcantly differed by gender, we conducted a non-
parametric Mann–Whitney test [16]. We also performed a
geographic analysis of the place of death by calculating the
standardized mortality ratio (SMR) for three macroareas
(northern Italy, central Italy, and southern Italy/the
islands); the reference population was Italy’s general
population in the same period (1995–2006).
Mortality rate and temporal trends
To evaluate temporal trends in MCC mortality, based on the
multiple-cause-of-death database, we calculated the crude
mortality rate for each year and the mean mortality for the
entire period, assuming that the population remained stable
during the study period. This calculation was performed
using the Cuzick test for trend, which is an extension of the
Wilcoxon rank-sum test [17, 18], and considering deaths
due to MCC (n = 298). We also calculated the age-adjusted
mortality rate (and the 95% conﬁdence intervals; 95% CI)
for the entire period using a direct method of standardiza-
tion to account for differences in age distribution, consid-
ering the European population as reference.
Association between MCC and other cancers
To evaluate the potential association between MCC and
other primary cancers, we determined whether there was an
excess or deﬁcit of deaths due to these cancers among
deceased persons with MCC by making comparisons with
the general population of deceased persons. However, only
the underlying cause of death (and not other causes) is
available for the general population. Thus for this analysis,
we considered only the underlying cause of death. In par-
ticular, we compared the observed number of deaths due to
other primary cancers to the expected number. The
observed number was the number of deceased persons with
MCC who had a given primary cancer as the underlying
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persons with the given cancer as the underlying cause in
the same age general population of persons who died in the
same period. For the expected number of deaths, the data
source was Italy’s National Mortality Database; until 2003,
ICD-9 was used to code the underlying cause of death in
this database; since then, ICD-10 has been used (www.
who/int/classiﬁcations/icd/en/). The ratio of observed-to-
expected cases can be considered as standardised mortality
ratio (SMR)-like (herein referred to as ‘‘SMR’’) [13]. The
SMR was calculated for major groups of cancers and for
individual tumours. The 90% conﬁdence intervals were
calculated using either the Byar formula (for cancers for
which there were at least three deaths) [19] or assuming a
Poisson distribution of observed cases (for cancers with
fewer than three deaths).
Results
Information on the 351 deaths with MCC is reported in
Table 1. MCC mainly affected the elderly population
(median age at death: 75 years for men and 80 years for
women); 6.3% of the deaths occurred under 55 years of
age. The age distribution differed by gender (p\0.05): for
persons under 55 years of age, there were twice as many
men; for persons older than 85 years, there were three
times more women. For the 238 (67.8%) deaths with
known MCC stage, in most cases (n = 214) it was non-
localized (i.e., regional lymph nodes or distant site). The
sites of the distant metastases were skin, subcutaneous
tissue, distant lymph nodes, liver, lung, bone, central ner-
vous system (brain, leptomeninges, cerebellum, and spinal
cord), stomach, oesophagus, bone marrow, pleura, perito-
neum, and unspeciﬁed site. Of the 24 deaths with localized
MCC, for 18 of them MCC was the underlying cause of
death; in one-third of these cases, MCC was localized on
the face.
Of the 351 deaths with MCC, the underlying cause was
MCC for 298 deaths (Table 1). When considering other
relevant diseases or conditions reported anywhere on the
death certiﬁcate (data not shown in Table 1), for 190 deaths
(54.1%) none were recorded, whereas for the remaining
161 deaths, the other diseases or conditions were other
primary cancers (n = 38 certiﬁcates), cardiovascular dis-
ease (n = 45), genitourinary diseases (n = 27), diabetes
(n = 20), respiratory disease (n = 6), digestive disease
(n = 5) and other diseases (n = 14); 7 death certiﬁcates
mentioned a condition associated with chronic immune
suppression [HIV/AIDS (n = 3), kidney transplant (n = 2),
and autoimmune disease (Bechet’s disease (n = 1), and
autoimmune haemolytic anemia (n = 1))].
Thirty-eight certiﬁcates mentioned 41 primary cancers
in addition to MCC (Table 2), as underlying cause
(n = 26) or other causes (n = 15). Triple primary cancers
(i.e., two cancers in addition to MCC) were recorded on 3
certiﬁcates: chronic lymphocytic leukemia and Kaposi’s
sarcoma; thyroid and adrenal gland cancers; and larynx
cancer and non-Hodgkin’s lymphoma.
Regarding the association between MCC and other pri-
mary cancers, there was a signiﬁcant deﬁcit for all solid
tumours combined and individually, except for female
breast cancer and uterine cervix cancer, for which a non-
signiﬁcant excess was found. A non-signiﬁcant (though
borderline) excess was found for malignant neoplasms of
lymphocytic and haematopoietic tissue; however, signiﬁ-
cant excesses were found for the single entities chronic
lymphocytic leukemia and Waldenstro ¨m’s macroglobulin-
emia and non-signiﬁcant excesses for chronic myeloid
leukemia, acute leukemia and non-Hodgkin’s lymphoma.
The crude mortality rate for the study period was 0.04
per 100,000 population; the age-adjusted rate was 0.027
per 100,000 population (95% CI: 0.027–0.034). There was
a signiﬁcant trend of increase in the crude mortality rate
(p\0.005) (Fig. 1).
Table 1 Distribution of 351 deaths with Merkel cell carcinoma in
Italy (1995–2006)
Characteristics n (%)
Gender
Men 179 (51.0)
Women 172 (49.0)
Age at death
\60 33 (9.4)
60–74 110 (31.3)
75? 208 (59.3)
Anatomical site
Head and neck 21 (6.0)
Upper limb 11 (3.1)
Lower limb 39 (11.1)
Buttock 10 (2.8)
Unspeciﬁed 270 (76.9)
Stage at death
Local 24 (6.8)
Regional 27 (7.7)
Distant 187 (53.3)
Unstaged 113 (32.2)
Underlying cause of death
Merkel cell carcinoma 298 (84.9)
Primary cancers 26 (7.4)
Cardiovascular diseases 16 (4.6)
Digestive diseases 3 (0.9)
Respiratory diseases 3 (0.9)
Other causes 5 (1.4)
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MCC deaths in northern Italy (n = 185, SMR = 1.21, 90%
CI: 1.06–1.36), a non-signiﬁcant excess in central Italy
(n = 76, SMR = 1.11, 90% CI: 0.91–1.34) and a signiﬁ-
cant deﬁcit in southern Italy and the islands (n = 90,
SMR = 0.70, 90% CI: 0.58–0.83).
Discussion
Because MCC is so rare, there are few population-based
epidemiological data, most of which derive from cancer
registries and have only recently become available. In
Europe, the crude incidence was estimated to be 0.13 per
Table 2 Additional primary cancers in deaths with Merkel cell carcinoma
Cancer type or site ICD_9 ICD_10 Underlying cause of death Other’s cause
of death
n SMR 90% CI n
Solid cancers 140–199, 210–239 C00–C79 13 0.15 0.09–0.23 9
Digestive organs 150–159 C15–C26 7 0.20 0.09–0.37 –
Stomach 151 C16 1 0.14 0.01–0.67 1
Colon 153 C18 4 0.52 0.19–1.31 1
Liver 155 C22 1 0.16 0.01–0.77 –
Pancreas
a 157 C25 1 0.19 0.01–0.93 –
Lung, larynx 161–162 C32–C34 2 0.09 0.02–0.30 –
Female breast 174 C50 1 2.97 0.17–15.80 2
Skin, non-melanoma
b 173 C44 1 0.14 0.01–0.67 –
Kaposi’s sarcoma – C46 – – – 1
Uterine cervix 180.1 C53.1 1 16.80 0.50–47.44 –
Prostate 185 C61 1 0.22 0.01–0.67 –
Kidney 189 C64 – – – 1
Thyroid 193 C73 – – – 1
Adrenal gland 194.0 C74 – – – 1
Soft tissue sarcoma
c 171 C49 – – – 1
Lymphohaematopoietic cancers 200–208 C81–C96 13 1.62 0.96–2.58 6
Non-Hodgkin’s lymphoma 200, 202 C83, C85 3 1.05 0.28–2.67 1
Multiple myeloma 203 C90 1 0.62 0.03–2.97 –
Acute leukemia 204.0, 205.0 C91.0, C92.5 1
d 4.10 0.25–23.72 1
e
Chronic lymphocytic leukemia 204.1 C91.1 3 4.07 1.17–11.08 4
Chronic myeloid leukemia 205.1 C92.1 2 5.12 0.89–15.74 –
Waldenstro ¨m’s macroglobulinemia 273.3 C88 2 27.20 3.55–62.9 –
Primary myeloﬁbrosis – – 1 –
f ––
All cancers 140–239 C00–D48 26 0.26 0.18–0.36 15
a Neuroendocrine carcinoma
b Squamous cell carcinoma
c Sarcoma of large systemic blood vessels
d Myelomonocytic leukemia
e Lymphoid leukemia
f SMR could not be calculated for this entity
Fig. 1 Mortality trend for Merkel cell carcinoma in Italy
(1995–2006)
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123100,000 population in 1995–2002, based on pooled data on
‘‘endocrine carcinoma of the skin’’ from a network of
cancer registries participating in the RARECARE project
on rare cancers (http://www.rarecare.eu/rare_indicators/
rare_indicators.asp; Technical Report); the only published
data on MCC incidence for individual European countries
are from Denmark (crude incidence = 0.22) and Sweden
(0.42 for men and 0.33 for women) [11, 12]. In Italy, the
crude incidence in 2001–2005 was 0.28 (95% CI:
0.25–0.32), and the age-adjusted incidence (using the
standard European population) was 0.16 (95% CI:
0.14–0.19) (AIRTUM, personal communication). In both
Europe and the United States, there seems to be a trend of
increase in incidence [3, 11, 12, 20].
To contribute to the knowledge of the occurrence of this
tumour and its relationship with other diseases, we used
mortality data, which are exhaustive in terms of population
coverage and are readily available. In particular, we used
the multiple-cause-of-death database, given that in the
ofﬁcial National Mortality Database, it is not possible to
distinguish MCC because it is coded among ‘‘other
malignant neoplasms of skin’’ (also known as ‘‘non-mela-
noma skin cancer’’).
We report one of the highest numbers of deaths of MCC
in Europe. In fact, we found, in a single country, 351 MCC
deaths in 12 years (1995–2006), compared to the estimated
457 deaths in 8 years (1995–2002) for all of the European
countries included in RARECARE (www.rarecare.eu). We
also found a signiﬁcant increase over time in the crude
mortality rates, which is consistent with the increases in
incidence in a similar time period in both Europe and the
United States [3, 11, 12, 20].
Our crude mortality rate for MCC in 1995–2006 (0.04)
is consistent with the 0.05 crude mortality rate for
‘‘endocrine carcinoma of the skin’’ for 1995–2002 reported
by RARECARE, which, however, was not based on actual
mortality data and was estimated based on incidence rates
multiplied by the fatality proportion, under the assumption
of constant incidence and survival rates (www.rarecare.eu).
However, both our standardized mortality (0.027) and
crude mortality (0.04), as well as the rate reported by
RARECARE, are much lower than the 0.16 standardized
incidence estimated for 2001–2006 in Italy (AIRTUM) and
the crude incidence estimated for Europe (0.13, based on
1,082 cases). These ﬁndings are unexpected, given that
MCC is generally considered to be highly aggressive and
lethal, and mortality would be expected to reﬂect inci-
dence. There are a number of possible explanations for this,
at least with regard to Italy. In particular, the mortality rate
for MCC based on death certiﬁcates may constitute an
underestimate. Moreover, the period of analysis in our
study was longer than the periods considered in the inci-
dence estimates, and both incidence and mortality have
increased in recent years. Another explanation could be
that the incidence estimate for Italy is based on data from
the cancer registries, which cover only one-third of the
national population. Finally, these ﬁndings could suggest
that MCC is not as lethal as currently believed.
To the best of our knowledge, this is the only nationwide
population-based mortality rate based on actual data,
although a rate has been reported for Western Australia
[21].
Our results conﬁrm that MCC mainly affects the elderly
population [1–3]. Moreover, MCC was associated with a
signiﬁcant decrease in the median age at death (men:
75 years for MCC vs. 80 years for the general population;
women: 80 and 85.7 years, respectively). Although this
decrease could be considered as an indication of the
lethality of the disease, this cannot be thoroughly evaluated
because we have no information on the time of diagnosis.
Regarding the anatomical site of MCC, it must be
considered that this information was not provided on more
than three-fourths of the death certiﬁcates, and it is likely
that in some of these cases the MCC was occult (nodal or
visceral disease with no primary tumour identiﬁed), which
has been reported in a number of MCC series [22].
Regarding the diffusion of the tumour, for which data were
more complete, in most cases the metastases were multiple
metastases beyond regional lymph nodes, both in typical
sites (e.g., liver) and less typical sites (e.g., gastrointestinal
tract), as well as some unusual sites (e.g., spinal cord). The
ﬁnding that MCC was the underlying cause of death for
most of the 24 deaths with localized tumour can be
explained by the fact that MCC is known to invade deep
extradermal structures. On two death certiﬁcates, MCC
involving the parotid gland was reported as the underlying
cause of death, yet we did not calculate the excess because
they were probably not salivary gland primaries. However,
in a recent study on MCC, salivary gland cancer was
considered as a second primary and a signiﬁcant excess
was found, though the authors discuss the difﬁculty in
making this distinction [8]. In fact, the presence of salivary
gland cancer and MCC could be indicative of: (1) MCC
that developed in the skin and inﬁltrated the parotid gland;
(2); MCC-like primary small cell carcinoma of the parotid
gland, which is closely related to cutaneous MCC [23]; or
(3) parotid metastases of MCC. In fact, we found a third
death certiﬁcate with non-localized MCC mentioning par-
otid metastases of MCC.
The non-neoplastic diseases reported on the death cer-
tiﬁcates are typical causes of death in the elderly. With
regard to diabetes, though there is no way of differentiating
type I from type II on death certiﬁcates, 3 of the 20 cer-
tiﬁcates mentioning diabetes reported type I, which is
considered to be an autoimmune disease. MCC has been
shown to be associated with autoimmune diseases [24],
Cancer Causes Control (2011) 22:1521–1527 1525
123solid-organ transplantation [5, 6] and, though with con-
ﬂicting results, AIDS/HIV-infection [6, 7]; in our study, we
only identiﬁed a few cases of these conditions.
In comparing our results on associations between MCC
and other cancers to the results of other studies, it must be
considered that all of the other studies are based on
incidence data [8, 9, 11]. In our analysis, we were only
able to consider the tumour indicated as the underlying
cause of death. Moreover, death certiﬁcates do not provide
information on temporal order (i.e., whether MCC occurs
as ﬁrst or second primary). The excess found for lym-
phatic/haematologic malignancies, though not signiﬁcant,
is consistent with the ﬁndings of previous studies [8, 9,
11]. It is also consistent with our ﬁnding that 19 of the 41
tumours found anywhere on the death certiﬁcate were
lymphatic/haematologic malignancies. We also found a
signiﬁcant deﬁcit for solid tumours overall; in the only
previous study that calculated the risk for all solid
tumours, a slight (though not signiﬁcant) risk was found
[8]. We also found a four fold excess for chronic lym-
phocytic leukemia, which is the only cancer for which all
of the available incidence studies consistently report a
signiﬁcant association with MCC [8, 25]; our ﬁnding is
the ﬁrst to conﬁrm this association with mortality data.
The association between MCC and chronic lymphocytic
leukemia is consistent with studies that have demonstrated
the importance of immunologic factors in MCC [8–11].
Of interest is the ﬁnding that chronic lymphocytic leuke-
mia was also indicated on another 4 death certiﬁcates as a
non-underlying cause. We also found a slight, yet not
signiﬁcant, excess for non-Hodgkin’s lymphoma, as also
reported in Finland [9]; signiﬁcant excesses were found in
Denmark and the SEER study [8, 20]. Regarding the
excess for Waldenstro ¨m’s macroglobulinemia (a rare
lymphoplasmacytic lymphoma), an association with MCC
has never been reported previously. This is of interest
because certain immune-related and/or infectious condi-
tions are strongly associated with an increased risk of
Waldenstro ¨m’s macroglobulinemia [26]. Although it was
not possible to determine the temporal sequence of these
tumours, our results could indicate that these diseases
share some etiologic or risk factors. We also found non-
signiﬁcant excesses for chronic myeloid leukemia and
acute leukemia.
Differently from incidence studies [9], we did not
observe an excess for squamous or basal cell carcinoma of
the skin. However, this is not surprising, in that non-lethal
tumours are generally not reported on death certiﬁcates.
The indication of pancreatic neuroendocrine neoplasm as
the underlying cause on a single certiﬁcate is of interest
because of the rarity of this neoplasm as a primary cancer;
however, a metastatic MCC mimicking primary pancreatic
endocrine tumour cannot be ruled out. Of the three
certiﬁcates that mentioned three primary cancers each, that
which mentioned MCC, chronic lymphocytic leukemia and
Kaposi’s sarcoma is of interest in light of the detection of
Merkel-cell-polyomavirus in a number of cases of Kaposi’s
sarcoma [4, 27] and similar case reports [28].
The pattern of additional cancers revealed by our results
is similar to that found in a previous study on classic
Kaposi’s sarcoma [13], another virus-related skin cancer.
In particular, for both MCC and classic Kaposi’s sarcoma,
there was a signiﬁcant deﬁcit for solid cancers, an excess
for chronic lymphocytic leukemia, and advanced age at
death. However, there were also some differences: differ-
ent percentage of deaths due to the disease (85% for MCC
vs. 12% for classic Kaposi’s sarcoma); a predominance of
men for Kaposi’s sarcoma; and a greater association with
immune suppression for Kaposi’s sarcoma.
The north–south gradient in the risk of MCC mortality
seems to be contradictory, in that sun exposure (i.e., one of
the few known risk factors for MCC [2, 3]) is higher in
southern Italy. Although we cannot explain this ﬁnding, we
can speculate that it is related to differences in the geo-
graphic distribution of oncology treatment centres and the
rate of MCC underdiagnosis.
In drawing conclusions, some potential limits need to be
mentioned. Although this study includes data from a large
population over a reasonably long period of time, since
MCC is very rare the numbers were extremely small when
evaluating the association with other primary cancers,
which may have affected the SMR estimates. Moreover,
we were not able to evaluate associations with non-lethal
tumours or cancer that was cured in the past, in that these
conditions are not included on death certiﬁcates. Regarding
ascertainment bias, we are reasonably sure that there were
no false-positives, simply because of the peculiarity of the
term ‘‘Merkel’’. We also paid particular attention to all of
the possible misspellings and pathologies whose name
could have created confusion. However, we cannot exclude
the possibility of false-negatives, a limitation that is
inherent to death certiﬁcates. We may also have failed to
identify cases indicated as ‘‘trabecular carcinoma of the
skin’’ and ‘‘cutaneous neuroendocrine carcinoma’’ (without
the term ‘‘Merkel’’). However, the most prevalent name
currently used dates back to after 1992, when the impor-
tance of staining for cytokeratin-20 was published for the
differential diagnosis of MCC [29], and our data refer to
1995 and beyond.
Despite these limitations, the in-depth review of multi-
ple-cause-of-death records can be an important source of
clinical information. Although using mortality data does
not allow us to identify all persons with MCC, they do
provide us with a conservative population-based estimate
of its occurrence and of its association with other primary
cancers.
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